There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter.
Compass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy firm Mind Medicine is aiming to follow suit by up-listing its shares on
UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic m
US biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a $75 million stock market launch, as the firm gears up for clinical trials of its lead drug for r
California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last week, seeking $115 million in funding for projects including a CAR
Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s